Table 1.
SGLT2 inhibitors under phase II and phase III clinical trials.
| Drug | Company | Phase of clinical trial |
|---|---|---|
| Dapagliflozin (BMS-512148) | Bristol-Myers Squibb/AstraZeneca | Phase III (approved in Australia (Oct 2012), Europe (Nov 2012), Mexico (Mar 2013), New Zealand (June 2013), Brazil (July 2013), Argentina (Sep 2013), US (Jan 2014), and Japan (Mar 2014)) |
|
| ||
| Canagliflozin (TA-7284, JAJ-28431754) | Johnson and Johnson and Mitsubishi Tanabe Pharma | Phase III (approved in US (Mar 2013) and Europe (Nov 2013)) |
|
| ||
| Empagliflozin (BI-10773) | Boehringer Ingelheim/Lilly | Phase III (approved in Europe (May 2014)) |
|
| ||
| Ipragliflozin (ASP-1941) | Astellas Pharma and Kotobuki Pharmaceutical Company | Phase III (approved in Japan (Jan 2014) |
|
| ||
| Tofogliflozin (CSG452) | Roche/Chugai | Phase III |
|
| ||
| Luseogliflozin (TS-071) | Taisho | Phase III |
|
| ||
| BI 44847 | Boehringer Ingelheim | Phase III |
|
| ||
| LX4211 | Lexicon Pharmaceutical | Phase II |
|
| ||
| PF-04971729 | Pfizer | Phase II |
|
| ||
| EGT0001442 | Theracos | Phase II |
|
| ||
| GW 869682 | GlaxoSmithKline | Phase II |